Capital Fund Management S.A. Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Capital Fund Management S.A. bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 28,058 shares of the company’s stock, valued at approximately $1,083,000.

Several other hedge funds also recently made changes to their positions in PTGX. Renaissance Technologies LLC lifted its stake in Protagonist Therapeutics by 53.4% during the fourth quarter. Renaissance Technologies LLC now owns 221,167 shares of the company’s stock worth $8,537,000 after purchasing an additional 77,000 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Protagonist Therapeutics by 13.1% in the 4th quarter. Invesco Ltd. now owns 738,952 shares of the company’s stock valued at $28,524,000 after buying an additional 85,800 shares during the period. Bank of Montreal Can grew its position in shares of Protagonist Therapeutics by 4.5% during the 4th quarter. Bank of Montreal Can now owns 6,250 shares of the company’s stock valued at $241,000 after buying an additional 270 shares during the last quarter. Sierra Summit Advisors LLC grew its position in shares of Protagonist Therapeutics by 5.3% during the 4th quarter. Sierra Summit Advisors LLC now owns 22,282 shares of the company’s stock valued at $860,000 after buying an additional 1,115 shares during the last quarter. Finally, Aviva PLC acquired a new stake in Protagonist Therapeutics during the fourth quarter worth about $565,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Up 4.3 %

Shares of PTGX opened at $46.95 on Wednesday. The firm has a market capitalization of $2.88 billion, a PE ratio of 17.65 and a beta of 2.30. The firm has a 50-day moving average price of $44.37 and a 200 day moving average price of $42.77. Protagonist Therapeutics, Inc. has a 52-week low of $24.22 and a 52-week high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $170.64 million for the quarter, compared to analysts’ expectations of $56.65 million. On average, equities analysts expect that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Insider Transactions at Protagonist Therapeutics

In other news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total value of $204,606.62. Following the completion of the sale, the chief executive officer now owns 540,260 shares in the company, valued at $20,627,126.80. This represents a 0.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Arturo Md Molina sold 30,514 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $55.74, for a total value of $1,700,850.36. Following the sale, the insider now owns 83,892 shares of the company’s stock, valued at $4,676,140.08. The trade was a 26.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,776 shares of company stock valued at $3,585,010 in the last quarter. Insiders own 5.40% of the company’s stock.

Wall Street Analyst Weigh In

PTGX has been the subject of several recent research reports. BTIG Research set a $73.00 target price on Protagonist Therapeutics in a report on Monday, March 3rd. The Goldman Sachs Group lowered their price objective on Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating for the company in a research note on Monday, February 24th. JPMorgan Chase & Co. raised their target price on Protagonist Therapeutics from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Protagonist Therapeutics in a research report on Thursday, April 10th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $65.44.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.